

Original Article**Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery***

*Feridoun Sabzi¹, Gholam Reza Moradi², Heidar Dadkhah³,
Alireza Poormotaabed⁴, Samsam Dabiri⁴*

Abstract

BACKGROUND: The low dose aprotinin consistently reduces blood and transfusion requirement in adults during cardiac surgical procedures but its effectiveness in some ethnical groups were debated and controversy about its effect on mortality and morbidity precludes its routine use. This study was designated to determine whether a low dose of aprotinin causes more mortality and morbidity when used after coronary artery bypass grafting (CABG) surgery.

METHODS: In a clinical trial study, 380 patients in placebo and 273 patients in aprotinin group were enrolled. A test dose before skin incision and 2 million kallikrein inactivation units (KIU) during initiation of cardiopulmonary bypass (CPB) were given to patients. Differences in quantity of blood transfusion, morbidity and mortality were analyzed. Multivariable analysis was performed to determine risk factors for mortality.

RESULTS: Decreased blood product transfusions and increased rate of morbidity were found in the aprotinin group. Independent predictors for increased number of transfusion were aspirin continued before operation and small body mass index (BMI) but there was a significant difference in mortality and morbidity between two groups.

CONCLUSIONS: In patients undergoing CABG procedure, low dose aprotinin is effective in attenuating post bypass coagulopathy and decreasing blood product use, but it increases morbidity.

KEYWORDS: Aprotinin, Coronary Artery Bypass Graft, Blood Transfusion, Mortality.

J Res Med Sci 2012; 17(1): 74–82

Cardiovascular surgery is associated with a significant consumption of allogeneic blood products often as a result of acquired hemostatic defect and incomplete hemostasis. Aprotinin has been repeatedly shown to reduce blood loss and transfusion requirements after cardiopulmonary bypass (CPB) in adults by multiple mechanisms, which include inhibition of fibrinolysis and preservation of platelet function through its antagonism of the actions of plasmin and kal-

likrein. Its effect are especially notable in patients considered at increased risk of bleeding such as those receiving aspirin, those with infective endocarditis, and those undergoing repeat sternotomy. Studies about the effects of aprotinin in some ethnical groups have not demonstrated consistent results, with improved hemostasis and reduced transfusion in some race and increased morbidity and mortality noted in some others ethnical groups.¹⁻³ Reasons for these inconsistencies could involve

* This was derived from the results of a MSc thesis which was supported by Kermanshah University and Kermanshah University of Medical Science.

1- Associate Professor, Department of Cardiac Surgery, Emam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

2- Assistant Professor, Department of Cardiac Anesthesiology, Emam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

3- Assistant Professor, Department of Cardiac Surgery, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran.

4- Perfusionist, Department of Cardiac Surgery, Emam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Corresponding author: Gholamreza Moradi

E-mail: drmoradi2008@yahoo.com

ethnic, patient selection, complexity of coagulopathies after CPB, and variability of dosage regimens. Pharmacological agents to reduce bleeding have gained much interest, since they are readily available, easy to administer, can be used prophylactically, do not require the use of costly equipment and appear to be very efficacious. The perioperative uses of aprotinin have gained acceptance around the world for prophylactic reduction of allogeneic blood transfusion in operation.⁴⁻¹⁰ Mangano and associates found the use of aprotinin in patients undergoing coronary artery bypass grafting (CABG) to be associated with higher mortality and increased risk of renal and cardiac events in both short and long term studies.⁵ Ferguson and associates compared aprotinin with two other lysine analogues in high risk cardiac surgery. The aprotinin group had higher hospital mortality than two other groups.¹⁰ This finding resulted in controversies in aprotinin use in cardiac surgery all over the world. However, several problems have to be addressed for the clinical safety of aprotinin. Several studies have shown that response to aprotinin is related to internal fibrinolysis system of the patients.

The antifibrinolytic action of the aprotinin is based on different mechanisms. Aprotinin slows fibrinolysis and reduces factor VIIIa formation by inhibiting plasmin and kallikrein respectively. This different pathway of aprotinin action may be fully effective in some ethnic group or partially effective in other races. The aprotinin inhibits these pathways by multiple enzymes and receptors and deficiency of these receptors may be related to ethnic and race, as there are ethnical variability in blood coagulation and fibrinolysis system in response to other drugs.^{11, 12} To address this question, we performed a study in a single center in Kurdish population in Iran (Kermanshah, Kurdistan and Ilam).

Methods

This clinical trial study was approved by research ethics committee of Kermanshah University of Medical Sciences in September 2007.

Informed consent was obtained before enrolling each patient in the study. Between September 2007 and September 2008, 653 patients scheduled to undergo first time CABG and were randomized in a double blinded clinical trial to receive low dose aprotinin (Hungary Corporation), 2 million KIU (Kallikrein Inactivator Units) or placebo. Aprotinin was presented in clear vials each containing 100000 KIU in 20 ml 0.9 % saline solution.^{13,14} One of the anesthesiologist that not engaged in the patient care, made up the entire test solution and the trial drug was provided this anesthesiologist and was supplied in identical looking 500 ml bottles. 500 ml bags of sterile 0.9 % saline solution had a volume discarded (400 ml) and replaced with the same volume of test solution (400 ml aprotinin) so that all bags contained equal volumes (500 ml). These bottles were provided by anesthesiologist with sealed envelopes with the randomization codes to enable an individual patient's code to be broken in time of operation. With a computer generated random number, patients were consecutively allocated to one of the following two groups. Group A (n = 380), received 0.9% saline as placebo that was added to the pump prime. Group B (n=273), received 2000000 KIU aprotinin into the pump prime. These patients received a bag containing 400 ml aprotinin and 100 ml 0.9 saline solution that were added to the pump prime. The patients were selected according to similar risk of bleeding: patients undergoing CABG with left internal mammary artery (LIMA) in combination with saphenous vein. The patients with right internal mammary (RIMA) graft harvesting were excluded from the study (risk of bleeding is higher in RIMA harvesting than saphenous vein graft). Other exclusion criteria were recent use of antiplatelet agents other than aspirin, allergy to aprotinin, history of sternotomy, congenital bleeding disorder. The patients were also excluded if they had recent thrombolytic therapy (less than 1 day) or heparin (less than 4 hours) or warfarin (less than 3 days) preoperatively. Other exclusion criteria were left ventricular ejection fraction less than 25%,

impaired renal function (serum creatinine more than 2 mg/dl), combined valvular and CABG operation and diffuse and small coronary artery disease.

The conduct of the operation was performed according to technique of routine hospital anesthesia and we used a membrane oxygenator and cardiotomy suction for each patient. Bovine heparin was administered as a loading dose (300 IU/kg) and 20000 IU was added to the pump prime. Activated clotting time was maintained at more than 400 seconds before and after heparinization. Cell saver system and auto transfusion were not used. Homologous red blood cells were transfused during CPB if the patients hemoglobin was less than 7.0 g/dl and postoperatively if less than 8.0 g/dl or if there was excessive mediastinal bleeding. If the patient's condition warranted, platelets and fresh frozen plasma and cryoprecipitate were transfused. Variables such as age, weight, body mass index, blood products transfused intra operatively or post operatively and mediastinal tube drainage at 6 and 12 hours were recorded on a study protocol data sheet for each patient.

Electrocardiograms (ECG) changes between preoperative and postoperative period (performed on day one) with other's variable such as hemodynamic instability, cerebrovascular accident, renal and gastrointestinal complication and other complication were noted on the data sheet.

Preoperative and postoperative hemoglobin, creatinine phosphokinase myocardial band (CPK MB), troponin, and creatinine tests were also recorded. Evaluation of efficacy included the quantity of mediastinal tube drainage at 6 and 12 hours, incidence of reexploration for non surgical bleeding, proportion of patients requiring transfusion and comparison of the total number of blood units and each type of blood product (packed red cells, fresh frozen plasma, and platelet) transfused during the operation. Packed red blood cell concentrates were transfused when the hematocrit/hemoglobin (Hct/Hb) value was less than 0.20/7 g/dl. In the postoperative intensive care

unit (ICU) the threshold for blood transfusion was a Hct/Hb less than 0.25/8 g/dl. The indication for postoperative platelets, fresh frozen plasma or cryoprecipitate transfusion was the presence of active bleeding (more than 200 ml/h) and a laboratory demonstrated coagulation defect (platelet count less than 80×10^9 , PT or PTT more than $1.5 \times$ control value or fibrinogen level less than 1 g/l. Diagnosis of clinically myocardial infarction was made on evaluation of ECG changes and increase in cardiac isoenzymes or troponin. In-hospital mortality was defined as death from any cause after the CABG during hospitalization. Renal dysfunction required a postoperative serum creatinine level of more than 1.5 mg/dl with an increase over in preoperative baseline of at least 0.5 mg/dl. Cerebrovascular incidents included new onset stroke and coma.

Data analysis

Data were recorded by two dedicated nurses. The patients requiring reexploration for bleeding were excluded only if a documented site amenable to surgical repair was located. Categorical and continues variables were analyzed by χ^2 and student's t-test, respectively. Two groups of patients were compared to determine the effect of aspirin on the proportion of patients transfused and units of blood products transfused in each treatment group. The aspirin group was defined as those patients who received aspirin 6 days before operation and no-aspirin group included those patients who did not receive aspirin 6 days before operation. Multivariable logistic regression was performed to determine predictors of transfusion volume. Statistical test were performed using the SPSS software version 11.5 and considered significant if p value was less than 0.05.

Results

Seven hundred patients were included in the study. Twelve of those patients in the aprotinin group who were explored and found to have surgical bleeding were excluded from analysis. Fifteen patients were also excluded due to diffuse coronary artery disease, small coronary

artery disease, antiplatelet agents other than aspirin, combined valvular and CABG operation, left ventricular ejection fraction (EF) less than 25%, impaired renal function, history of sternotomy, right internal mammary artery (RIMA) use and non-Kurdish patients in aprotinin group. Twenty patients were excluded from placebo group due to diffuse and small coronary disease, $EF \leq 25\%$, combined valvular and CABG operation and surgical bleeding (Diagram 1).

150 patients of each group were on aspirin preoperatively. Aprotinin and placebo groups were similar for age, weight, body surface

area, gender and rate of urgent cases per group. There was no difference between groups in number of units of blood given on CPB, pump time and hemoglobin level (Table 1). Chest tubes drainage at 6 hours postoperatively was significantly less in the aprotinin treated group for the total population and significantly less in the aspirin and non aspirin group too. These differences in drainage remained significant at 12 hours (Table 2).

Table 3 shows the mean number of blood products transfusion (packed red blood cells, fresh frozen plasma, platelets). The proportion of patients with transfusion was significantly




Diagram 1. Profile of the study

Table 1. Preoperative factors in the two study groups

Variables	Aprotinin (n=273)	Placebo (n=380)	P -value
Age (year, mean with range)	60.8 (34-76)	63.2 (38-79)	> 0.05
Gender (% female)	30%	28%	> 0.05
Emergency case (%)	25%	27%	> 0.05
Pump time (minutes)	82.2 ± 2.1	85 ± 3.2	> 0.05
Preoperative hemoglobin (g/dl)	14.5 ± 1.1	14.5 ± 1.2	> 0.05

less in the aprotinin treated group when compared to placebo group. The same was true for the aspirin and no aspirin groups when the aprotinin group were compared with the placebo treated patients. The proportion of patients receiving platelets and fresh frozen plasma were significantly less in all aprotinin treated groups. Independent predictors for both risk of transfusion and number of transfusion were small body mass index and aspirin administered preoperatively within 6 days of surgery. Preoperative hemoglobin below 12 g/dl and age more than 70 years predicted a greater number of transfusions (Table 4). Treatment with placebo was found to be a statistically significant predictor of transfusion and greater number of transfusion.

Morbidity was not similar for each group. The rate of re-exploration for mediastinal hemorrhage (3% in aprotinin vs. 7% in placebo group, $p < 0.05$), cerebrovascular accident (1.1 vs. 4%), MI (6% in aprotinin vs. 3% in placebo group) and rate of increased creatinine level of more than 2 mg/dl (aprotinin 7% vs. 2% placebo), mortality and intra aortic balloon pump using was different between two groups. Cardiac enzymes, CPKMB, and tropo-

nin were different between two groups when compared for MI (Table 5).

Discussion

Most of the previous studies used a high dose of aprotinin (6×10^6 KIU). However, by the use of a much lower dose of aprotinin rather than full dose, many investigators intended to reduce the cost per patient, maintain efficacy and extend the use of aprotinin to all patients needing cardiac surgery not just high risk patients such as those need repeated operation or complex procedures.¹⁵

Although the chest tube drainage was significantly reduced in aprotinin group patients, the important reduction in proportion of patients transfused and number of units transfused did not far outweigh the extremely high risk of mortality and morbidity in postoperative period. However, transfusion reduction is a more sensitive indicator of the effect of aprotinin. This would be especially true in patients on aspirin within 6 days before operation and in small patients.

Although safety was difficult to prove in previous study,^{4,6} we showed in this study that aprotinin at this dose had a higher morbidity

Table 2. Chest tube drainage in the two study groups

Drainage	Aprotinin	Placebo	P -value
6 hours drainage (ml)			
Total	332 ± 32	536 ± 31	< 0.05
Aspirin group	434 ± 30	625 ± 41	< 0.05
No Aspirin group	341 ± 28	442 ± 31	< 0.05
12 hours drainage (ml)			
Total	459 ± 41	763 ± 31	< 0.05
Aspirin group	550 ± 31	830 ± 45	< 0.05
NO Aspirin group	450 ± 33	632 ± 28	< 0.05

Table 3. Transfusion requirements in the two groups of study

Variables	Aprotinin	Placebo	P -value
Total	2.5 ± 0.5	6.4 ± 0.66	< 0.05
Aspirin	3.2 ± 0.1	6.45 ± 0.6	< 0.05
No Aspirin	1.5 ± 0.33	4.5 ± 0.44	< 0.05
FFP			
Total	0.2 ± 0.1	4.2 ± 0.2	< 0.05
Aspirin	0.4 ± 0.2	3.5 ± 0.4	< 0.05
No Aspirin	0.1 ± 0.1	2.5 ± 0.5	< 0.05
Platelet			
Total	0.35 ± 0.2	1.1 ± 0.2	< 0.05
Aspirin	1.1 ± 0.5	2.1 ± 0.5	< 0.05
No Aspirin	0.5 ± 0.2/1	1.5 ± 0.1	< 0.05

and mortality. The antifibrinolytic effect of aprotinin is thought to result from the direct inhibition of plasmin, and in this dose, it also inhibits kallikrein, and kallikrein is involved to great extent and this inhibition reduces graft patency.¹⁶ Hayashida and colleagues showed that when low dose of aprotinin was used, increased levels of Alfa 2 plasmin inhibitor, plasminogen activator and decreased levels of D-Dimmer were measured after CPB as compared to control, thus supporting antifibrinolytic not thrombogenic effect.¹⁷ Reasons for these inconsistencies could involve ethnic, patient selection, increased complexity of coagulopathies after CPB, and variability of dosage regimens. The unsimilarity in rate of MI and increase in creatinine level between groups dose not support the safety of this aprotinin dose (Table 5). Although substantial increase in creatinine was reported in aprotinin treated patients; but occurrence of renal failure itself was not different between the groups. A similar trend was reported in another well known clinical trial and the evidences linking aprotinin to these side effects were strong.¹⁸ The other previous study attempting to address systematically the issue of mortality found aproti-

nin to be associated with reduced mortality and slightly higher risk of myocardial infarction; however, those analysis unlike our study included a mixture of cardiac surgical procedures (mitral valve, aortic valve, CABG). In addition, others have indicated concerns about inaccuracies in patient numbers, discrepancies in odds ratios and inappropriate application of inclusion criteria, causing doubt on conclusions draw from these previous systematic analysis.¹⁹⁻²¹ A report by Mangano et al. suggested that antifibrinolytic therapy, including aprotinin, increased mortality among patients undergoing CABG. The study used data from studies in which treatment groups assignment was described as randomized or controlled, thus treatment bias did not affect the results in this observational study.⁵ In retrospective analysis of cardiac surgery population at risk for stroke, Ronald and Dunning observed a significant decrease in the occurrence of stroke among patients administrated low dose aprotinin relative to placebo group.³ our investigation provided additional data describing the cerebrovascular effect of aprotinin. Other studies have shown high dose but not low dose aprotinin to

Table 4. Factors associated with risk of postoperative transfusion by logistic regression analysis

Variables	Odd ratio (95% CI)	P -value
Preoperative hemoglobin < 13	2.5 (1-4)	< 0.05
Age > 70 year	1.5 (0.6-2.5)	< 0.05
Aspirin	2.5 (1.5-4.5)	< 0.05
No Aspirin	5 (2.1-8.5)	< 0.05

Table 5. Comparison of postoperative complication between the two groups

Variables	Aprotinin (n = 273)	Placebo (n = 380)	P- value
Postoperative myocardial infarction	6%	3%	< 0.05
Postoperative cerebrovascular accident	1.1%	4%	< 0.05
Postoperative creatinine raising	7%	2%	< 0.05
Mortality	6%	2%	< 0.05
Intra-aortic balloon pump using	8%	3%	< 0.05

reduce the risk of stroke.²²

Unlike previous studies^{9,22-28} we showed that low dose aprotinin increased risk of post operative mortality, MI and graft thrombosis. The benefit of aprotinin-induced reduction in transfusion requirement and transfusion associated morbidity and mortality did not far outweigh the extremely high risk of mortality and morbidity, associated with low dose aprotinin administrations, as Westby pointed out in an editorial "Occluded grafts are a high price to pay for an average blood saving of 250 ml in the postoperative period",^{15, 29-38} We are obsessed with use of platelet inhibitors to promote graft patency, yet in the operation room, with the onslaught of surgically induced thrombin formation, we are giving aprotinin that promote platelet adhesion and aggrega-

tion. A balance must be reached with these two opposing goals.^{13, 14} Routine use of these hemostatic agents may lead to an increase in adverse events. One cannot discuss the benefit of this drug without discussing their potential risks. It would seem logical that along with increased efficacy there may be increased thrombotic risk. A more logical approach may be performed to reserve these pharmacologic therapies to Kurdish patients who are at high risk for transfusion.

Acknowledgments

This study was funded by the Imam Ali Heart Center, Kermanshah University of Medical Sciences. We appreciate the commitment of staff in the division of Cardiac Surgery at Imam Ali Heart Center.

Conflict of Interests

Authors have no conflict of interests.

Authors' Contributions

FS, GM, AP, SD conducted the study and drafted the paper. HD helped in preparing and editing the manuscript.

References

1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. *Lancet* 1987; 2(8571): 1289-91.
2. Weiss SJ. Tissue destruction by neutrophils. *N Engl J Med* 1989; 320(6): 365-76.
3. Ronald A, Dunning J. Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? *Interact Cardiovasc Thorac Surg* 2006; 5(6): 767-73.
4. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. *J Thorac Cardiovasc Surg* 1994; 107(3): 807-10.
5. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. *JAMA* 2007; 297(5): 471-9.

6. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. *N Engl J Med* 2006; 354(4): 353-65.
7. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. *N Engl J Med* 2008; 358(8): 784-93.
8. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. *Ann Thorac Surg* 2006; 81(1): 104-10.
9. Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. *Anesth Analg* 2006; 103(5): 1082-8.
10. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med* 2008; 358(22): 2319-31.
11. Forouhi NG, Rumley A, Lowe GD, McKeigue P, Sattar N. Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians relative to Europeans. *Blood Coagul Fibrinolysis* 2003; 14(8): 755-60.
12. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1. *J Thorac Cardiovasc Surg* 2000; 120(2): 370-8.
13. Rossi M, Storti S, Martinelli L, Varano C, Marra R, Zamparelli R, et al. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system. *J Cardiothorac Vasc Anesth* 1997; 11(7): 835-9.
14. Maccario M, Fumagalli C, Deangelis R, Delfino R, Pergolo A, Dottori V, et al. [Comparison between low and high doses of aprotinin in heart surgery]. *Minerva Anestesiol* 1994; 60(6): 315-20.
15. Despotis GJ, Filos KS, Zoys TN, Hogue CW, Jr., Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. *Anesth Analg* 1996; 82(1): 13-21.
16. El RS, Mestres CA, LaDuca FM, Zucker ML. Racial and ethnic differences in warfarin response. *J Heart Valve Dis* 2004; 13(1): 15-21.
17. Westaby S, Katsumata T. Aprotinin and vein graft occlusion--the controversy continues. *J Thorac Cardiovasc Surg* 1998; 116(5): 731-3.
18. Yu HY, Liu CH, Chen YS, Wang SS, Chu SH, Lin FY. Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement. *J Formos Med Assoc* 2005; 104(4): 236-43.
19. Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. *Can J Anaesth* 1992; 39(4): 353-65.
20. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. *Ann Thorac Surg* 1993; 55(4): 971-6.
21. Kertai MD, Varga KS, Royston D, London MJ, Szabolcs Z, Grebenik CR, et al. Aprotinin and perioperative complications in cardiac surgery. *J Cardiovasc Surg (Torino)* 2007; 48(6): 761-72.
22. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. *Thromb Haemost* 1988; 59(1): 62-7.
23. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 1997; 114(2): 261-9.
24. Mouton R, Finch D, Davies I, Binks A, Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. *Lancet* 2008; 371(9611): 475-82.
25. Koster A, Buz S, Krabatsch T, Dehmel F, Kuppe H, Hetzer R, et al. High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation. *J Thorac Cardiovasc Surg* 2008; 135(3): 685-7.
26. Murkin JM. Attenuation of neurologic injury during cardiac surgery. *Ann Thorac Surg* 2001; 72(5): S1838-S1844.
27. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. *J Thorac Cardiovasc Surg* 2004; 128(3): 442-8.
28. Kain K, Catto AJ, Grant PJ. Impaired fibrinolysis and increased fibrinogen levels in South Asian subjects. *Atherosclerosis* 2001; 156(2): 457-61.
29. van OW, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. *Ann Thorac Surg* 1987; 44(6): 640-5.
30. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. *J Thorac Cardiovasc Surg* 1998; 116(5): 716-30.

31. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, et al. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. *Ann Thorac Surg* 2010; 89(5): 1489-95.
32. Ovrum E, Tangen G, Tollofsrud S, Ringdal MA, Oystese R, Istad R. Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. *Interact Cardiovasc Thorac Surg* 2010; 10(4): 545-8.
33. Stamou SC, Reames MK, Skipper E, Stiegel RM, Nussbaum M, Geller R, et al. Aprotinin in cardiac surgery patients: is the risk worth the benefit? *Eur J Cardiothorac Surg* 2009; 36(5): 869-75.
34. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. *CMAJ* 2009; 180(2): 183-93.
35. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. *Anesth Analg* 2008; 107(6): 1783-90.
36. Mir Mohammad Sadeghi M, Arasteh M, Gharipour M, Nilfroush P, Shamsolketabi H, Etesampour A, et al. Evaluation of accuracy of Euroscore risk model in prediction of perioperative mortality after coronary bypass graft surgery in Isfahan. *J Res Med Sci* 2011; 16(6): 787-92.
37. Mir Mohammad Sadeghi M, Gharipour M, Nilfroush P, Shamsolkotabi H, Sadeghi HM, Kiani A, et al. Influence of the timing of cardiac catheterization and amount of contrast media on acute renal failure after cardiac surgery. *J Res Med Sci* 2011; 16(4): 502-8.
38. Taghipour HR, Naseri MH, Safiarian R, Dadjoo Y, Pishgoo B, Mohebbi HA, et al. Quality of life one year after coronary artery bypass graft surgery. *Iran Red Crescent Med J* 2011; 13(3): 171-7.